Citations 1
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
Johnson, Isla McKerrow , Karrar, Omer , Rana, Masooma , Iftikhar, Moazah, Chen, Sunny , Saliba, Antoine N. , Al‐Kali, Aref , Begna, Kebede H. , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Hermann, Joerg, Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N. , Johnson, Isla M, Saliba, Antoine N , Al-Kali, Aref , Alkhateeb, Hassan B , Shah, Mithun V , Pardanani, Animesh , Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N , McCullough, Kristen , Alkhateeb, Hassan B. , Hogan, William J. , Shah, Meera
British Journal of Haematology | February 5, 2024 | Volume: 204 | Issue: 4 | Pages: 1232-1237
SummaryAmong 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non‐ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A‐mutated cases less likely (p < 0.01) to be affected. Treatment‐emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination.